Neuropace Inc
NASDAQ:NPCE
Neuropace Inc
Net Income (Common)
Neuropace Inc
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Neuropace Inc
NASDAQ:NPCE
|
Net Income (Common)
-$33m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Becton Dickinson and Co
NYSE:BDX
|
Net Income (Common)
$1.2B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
6%
|
CAGR 10-Years
3%
|
|
Boston Scientific Corp
NYSE:BSX
|
Net Income (Common)
$1.8B
|
CAGR 3-Years
106%
|
CAGR 5-Years
0%
|
CAGR 10-Years
17%
|
|
Stryker Corp
NYSE:SYK
|
Net Income (Common)
$3.4B
|
CAGR 3-Years
34%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
16%
|
|
Abbott Laboratories
NYSE:ABT
|
Net Income (Common)
$5.6B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
17%
|
CAGR 10-Years
9%
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Net Income (Common)
$2B
|
CAGR 3-Years
19%
|
CAGR 5-Years
12%
|
CAGR 10-Years
14%
|
See Also
What is Neuropace Inc's Net Income (Common)?
Net Income (Common)
-33m
USD
Based on the financial report for Dec 31, 2023, Neuropace Inc's Net Income (Common) amounts to -33m USD.
What is Neuropace Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
-11%
Over the last year, the Net Income (Common) growth was 30%. The average annual Net Income (Common) growth rates for Neuropace Inc have been -11% over the past three years .